Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nilotinib.

Greg L Plosker1, Dean M Robinson

  • 1Wolters Kluwer Health Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|March 6, 2008
PubMed
Summary
This summary is machine-generated.

Nilotinib shows significant efficacy in treating chronic myeloid leukaemia (CML) resistant to imatinib. This tyrosine kinase inhibitor achieved major cytogenetic response in 48% of chronic-phase CML patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis.

CNS drugs·2020
Same author

Asenapine: A Review in Schizophrenia.

CNS drugs·2016
Same author

AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus.

Drugs·2015
Same author

13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.

Drugs·2015
Same author

Acamprosate: A Review of Its Use in Alcohol Dependence.

Drugs·2015
Same author

Diclofenac sodium injection (akis(®), dicloin (®)): a review of its use in the management of pain.

Clinical drug investigation·2015
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Nilotinib is an oral BCR-ABL tyrosine kinase inhibitor.
  • It is used for imatinib-resistant or -intolerant Philadelphia chromosome-positive chronic myeloid leukaemia (CML).

Purpose of the Study:

  • To evaluate the efficacy and safety of nilotinib in a phase I/II trial.
  • To establish the optimal dosage regimen for nilotinib in CML treatment.

Main Methods:

  • Phase I/II clinical trial involving patients with CML in different phases (chronic, accelerated, blast crisis).
  • Nilotinib administered orally.
  • Primary endpoints included major cytogenetic response in chronic phase and hematologic response in accelerated and blast crisis phases.

Main Results:

Related Experiment Videos

  • In chronic-phase CML, 48% of 280 patients achieved major cytogenetic response.
  • In accelerated-phase CML, 47% achieved hematologic response.
  • In blast crisis CML, 39% achieved hematologic response.
  • Nilotinib was effective in patients with BCR-ABL mutations (excluding T315I).
  • Adverse events were generally mild to moderate, with Grade 3/4 neutropenia and thrombocytopenia reported in 29% each.

Conclusions:

  • Nilotinib demonstrates significant clinical efficacy across different phases of Philadelphia chromosome-positive CML.
  • It is an effective treatment option for imatinib-resistant or -intolerant CML patients.
  • Nilotinib is generally well-tolerated with manageable adverse events.